公开(公告)号：US20240355476A1

公开(公告)日：2024-10-24

申请号：US18761410

申请日：2024-07-02

Applicant: THE UNIVERSITY OF CHICAGO

Inventor： Suzanne D. CONZEN ,  Lei HUANG ,  Maria KOCHERGINSKY ,  Diana SZYMANSKI

IPC: G16H50/20 ,  C12Q1/6809 ,  C12Q1/6827 ,  C12Q1/6837 ,  C12Q1/6886 ,  G16H50/30

CPC classification number: G16H50/20 ,  C12Q1/6809 ,  C12Q1/6827 ,  C12Q1/6837 ,  C12Q1/6886 ,  G16H50/30 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/156 ,  C12Q2600/158

Abstract: Embodiments are directed to kits and methods of treating a breast cancer patient with a glucocorticoid receptor antagonist with or without an anticancer agent or compound after the patient has been determined to be susceptible to treatment with the glucocorticoid receptor antagonist.

公开(公告)号：US20240352120A1

公开(公告)日：2024-10-24

申请号：US18442934

申请日：2024-02-15

Applicant: Mayo Foundation for Medical Education and Research

Inventor： Lieping Chen ,  Scott E. Strome ,  Eugene D. Kwon, IV

IPC: C07K16/28 ,  A61K38/20 ,  A61K38/21 ,  A61K39/00 ,  C07K16/30 ,  C12N15/113 ,  C12Q1/6886 ,  G01N33/50 ,  G01N33/569 ,  G01N33/574

CPC classification number: C07K16/2803 ,  A61K38/2013 ,  A61K38/2026 ,  A61K38/2066 ,  A61K38/208 ,  A61K38/2086 ,  A61K38/212 ,  A61K38/215 ,  A61K38/217 ,  C07K16/2827 ,  C07K16/30 ,  C12N15/113 ,  C12N15/1138 ,  C12Q1/6886 ,  G01N33/5088 ,  G01N33/5091 ,  G01N33/56972 ,  G01N33/57407 ,  G01N33/57438 ,  G01N33/57484 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/76 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2320/30 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158

Abstract: The invention features methods of diagnosis by assessing B7-H1 expression in a tissue from a subject that has, or is suspected of having, cancer, methods of treatment with agents that interfere with B7-H1-receptor interaction, methods of selecting candidate subjects likely to benefit from cancer immunotherapy, and methods of inhibiting expression of B7-H1.

公开(公告)号：US12123058B2

公开(公告)日：2024-10-22

申请号：US16963948

申请日：2019-01-25

Applicant: SORBONNE UNIVERSITE ,  CTRE RECHERCHE PATHOLOGIES PROSTATIQUES ,  LIGUE NATIONALE CONTRE LE CANCER ,  ASSISTANCE PUBLIQUE HOPITAUX DE PARIS ,  INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ DE TOURS ,  CENTRE HOSPITALIER RÉGIONAL UNIVERSITAIRE DE TOURS

Inventor： Olivier Cussenot ,  Aurélie Kamoun ,  Aurélien De Reynies ,  Géraldine Cancel-Tassin ,  Gaëlle Fromont-Hankard

IPC: C12Q1/6886

CPC classification number: C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/154 ,  C12Q2600/158

Abstract: A method for predicting the risk of prostate cancer recurrence in a subject affected with prostate cancer, including: (a) providing a sample from the subject, (b) determining the TMPRSS/ERG fusion status of the sample, (c) if the sample is positive for TMPRSS/ERG fusion (Fus+), determining a molecular signature of the sample by measuring the expression level of at least 6 prostate cancer markers selected from the ANPEP, AZGP1, CHRNA2, COMP, KHDRBS3 and SFRP4, (d) comparing the molecular signature to a reference signature, and (e) assigning the subject to a risk group based on the correlation of the molecular signature with the reference signature, thereby predicting the risk of cancer recurrence in the subject.

公开(公告)号：US20240344152A1

公开(公告)日：2024-10-17

申请号：US18574720

申请日：2022-06-27

Applicant: Sun Genomics, Inc.

Inventor： Suneer Jain ,  Joann Lieu Phan ,  Divya Balachandran Nair ,  Thibaut Montagne

IPC: C12Q1/689 ,  C12Q1/6851 ,  C12Q1/6874

CPC classification number: C12Q1/689 ,  C12Q1/6851 ,  C12Q1/6874 ,  C12Q2600/118

Abstract: The present disclosure provides systems and methods for identifying microbial signatures from samples that determine discriminant features between healthy control populations and diseased subjects or populations with specific disorders. The microbial signatures are used to diagnose, prognose or determine risk and/or severity of a disease or disorder in a subject, such as autism spectrum disorder or irritable bowel syndrome.

公开(公告)号：US20240331873A1

公开(公告)日：2024-10-03

申请号：US18627253

申请日：2024-04-04

Applicant: GRAIL, LLC

Inventor： Oliver Claude Venn

IPC: G16H50/30 ,  C12Q1/6886 ,  G16B20/20 ,  G16B25/00 ,  G16B25/10 ,  G16B30/00

CPC classification number: G16H50/30 ,  C12Q1/6886 ,  G16B20/20 ,  G16B25/00 ,  G16B25/10 ,  G16B30/00 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/156

Abstract: Aspects of the invention relate to methods for tracking patient health by longitudinally tracking genetic variants in patients, such that it is possible to provide a tumor, or mutation, classification signature. Longitudinal tracking improves the ability to detect minimal residual disease (MRD; the small number of cells that remain in the patient after treatment and/or during remission) and/or treatment response at an early stage, both of which can help guide treatment decisions and guard against missing different intra-/inter-tumor responses in a patient.

公开(公告)号：US20240318230A1

公开(公告)日：2024-09-26

申请号：US18442591

申请日：2024-02-15

Applicant: Gen-Probe Incorporated

Inventor： Mehrdad MAJLESSI ,  Pamela DOUGLASS ,  Daniel KOLK

IPC: C12Q1/6811 ,  C12Q1/6816 ,  C12Q1/6851 ,  C12Q1/6853 ,  C12Q1/686 ,  C12Q1/6876 ,  C12Q1/6888 ,  C12Q1/70

CPC classification number: C12Q1/6811 ,  C12Q1/6816 ,  C12Q1/6851 ,  C12Q1/6853 ,  C12Q1/686 ,  C12Q1/6876 ,  C12Q1/6888 ,  C12Q1/701 ,  C12Q2600/118 ,  C12Q2600/166

Abstract: Compositions, methods, kits, and uses are provided for detecting or quantifying an Human Parainfluenza virus 1 (HPIV-1), HPIV-2, HPIV-3, and/or HPIV-4 nucleic acid, e.g., using nucleic acid amplification and hybridization assays. In some embodiments, the compositions, methods, kits, and uses target the HN gene of HPIV-1, HPIV-2, and/or HPIV-3 and/or the NP gene of HPIV-4.

公开(公告)号：US20240309440A1

公开(公告)日：2024-09-19

申请号：US18434556

申请日：2024-02-06

Applicant: The Regents of the University of California

Inventor： Minnie M. Sarwal ,  Tara K. Sigdel ,  Joshua Y. Yang

IPC: C12Q1/6853 ,  C12Q1/6813 ,  C12Q1/6827 ,  C12Q1/6876 ,  C12Q1/6883 ,  G01N33/53 ,  G01N33/68 ,  G01N33/70 ,  G16H10/40

CPC classification number: C12Q1/6853 ,  C12Q1/6813 ,  C12Q1/6827 ,  C12Q1/6876 ,  C12Q1/6883 ,  G01N33/53 ,  G01N33/68 ,  G01N33/6827 ,  G01N33/6839 ,  G16H10/40 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/154 ,  C12Q2600/158 ,  G01N33/70 ,  G01N2800/245 ,  G01N2800/347

Abstract: This present disclosure provides methods and compositions that can be used to quantify cfDNA in biofluids using a hybridization approach.

公开(公告)号：US20240301510A1

公开(公告)日：2024-09-12

申请号：US18037693

申请日：2021-11-18

Applicant: The Chinese University of Hong Kong

Inventor： Siew Chien NG ,  Ka Leung Francis CHAN ,  Qiaoyi LIANG

IPC: C12Q1/689 ,  C12N15/113 ,  C12Q1/6886

CPC classification number: C12Q1/689 ,  C12N15/113 ,  C12Q1/6886 ,  C12N2320/30 ,  C12Q2600/118

Abstract: A noninvasive methods for assessing the likelihood of recurrence of colorectal adenoma among patients who have previously undergone a procedure for colorectal cancer or adenoma removal as well as methods for reducing risk of colorectal adenoma recurrence in these patients. Kits useful for such methods are also provided.

公开(公告)号：US20240301506A1

公开(公告)日：2024-09-12

申请号：US18636932

申请日：2024-04-16

Applicant: PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE

Inventor： Javier CERDA INFANTE ,  Viviana MONTECINOS ACUÑA

IPC: C12Q1/6886 ,  G01N33/574

CPC classification number: C12Q1/6886 ,  G01N33/57434 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N2800/50

Abstract: Ex vivo method for the prognosis of metastasis in prostate cancer which comprises determining the level of expression of at least one of the following genes: NRP-1, MFAP4, NRIP3, THBS2, TNF, EDN1, EBF1 and GALNT16, in a biological sample that contains stromal cells of a prostate cancer primary tumor; and establish whether the expression of the genes NRP-1, MFAP4, NRIP3, THBS2, TNF, EDN1, EBF1 is increased or if the expression of the GALNT16 gene is diminished, which correlates with the prognosis of metastasis in prostate cancer. And a kit for predicting metastases in prostate cancer comprising means for quantifying the products of the genes NRP-1, MFAP4, NRIP3, THBS2, TNF, EDN1, EBF1 and GALNT16, in a sample comprising prostatic stromal cells.

公开(公告)号：US20240301498A1

公开(公告)日：2024-09-12

申请号：US18257383

申请日：2021-12-13

Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE ,  UNIVERSITÉ PAUL SABATIER TOULOUSE III ,  INSTITUT CLAUDIUS REGAUD

Inventor： Ataaillah BENHADDOU

IPC: C12Q1/6886 ,  G16B40/00 ,  G16H50/30

CPC classification number: C12Q1/6886 ,  G16B40/00 ,  G16H50/30 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/156

Abstract: The present invention relates to the field of cancer diagnostic methods for classifying cancer patients using a measure of the distribution of markers of DNA structure alterations within tumor genomic DNA sequence. The inventors have observed, in sarcomas, such as leiomyosarcoma, that the distribution of breakpoints within a set of selected transcription-associated chromosomal instability elements and a set of selected replication-associated chromosomal instability elements can be used to classify patients in groups according to a level of genome instability, which may be representative of a cancer evolution, a risk of occurrence of metastasis, a survival rate, or a sensibility to a cancer treatment. The present invention also relates to machine learning and trained classifiers for classifying patients having a cancer based upon a distribution of genomic DNA structure alterations or variations.